Intralytix, Inc. is a biotechnology company focused on the discovery, production and marketing of bacteriophage-based products to control bacterial pathogens in environmental, food processing, and medical settings.
Bacteriophages (bacteria-eater: from the Greek phago meaning "to eat" or "to develop at the expense of") are the most abundant microorganisms on earth. They are the natural enemies of bacteria. Lytic bacteriophages can very effectively kill their targeted specific bacteria without affecting anything else, ensuring an unprecedented level of safety for an antimicrobial.
In The News
Intralytix Receives Multimillion-Dollar Clinical Trial Award From NIAID to Manage Shigella Infections in Humans
Intralytix, Inc. announced today that it has received a multimillion-dollar grant (AI 148054) from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), for the clinical development of its bacteriophage therapy preparation for managing infections caused by the bacterial pathogen Shigella.
Intralytix Receives FDA Regulatory Clearance for Expanded Use in Red Meat for Phage-Based Salmonella Technology
Intralytix, Inc. announced today that its food safety product, SalmoFresh™, has been granted a supplement to its GRAS (Generally Recognized As Safe) recognized status from the Food and Drug Administration (FDA), which expands the use of SalmoFresh™ to ready-to-eat and raw red meat carcasses, subprimals and trimmings.
Intralytix Receives FDA Regulatory Clearance and Expanded Use, Including in Ground Beef, for Phage-Based E. coli Food Safety Product
Intralytix, Inc. announced today that its broader acting and expanded use food safety product, EcoShield PX™, has received GRAS (Generally Recognized As Safe) recognition from the Food and Drug Administration (FDA) for elimination of Escherichia coli O157:H7 and other Shiga toxin-producing E. coli (STEC) in many foods, including ground beef.
Intralytix Enters Into Joint Collaboration Agreement with the Eliava Foundation and Ferring Pharmaceuticals
Intralytix announces joint collaboration agreement to develop and commercialize new and innovative bacteriophage-based drugs in the field of Reproductive Medicine and Women's Health.